Navigation Links
MicroConstants China In-licenses Phase 2 Liver Cancer Drug from Canadian Pertinax Therapeutics
Date:9/9/2013

BEIJING, Sept. 9, 2013 /PRNewswire/ -- MicroConstants China Inc. has signed a definitive agreement to in-license the China rights for a promising Phase 2 liver cancer drug, PTX-9908, from Pertinax Therapeutics of Canada. MicroConstants China will be responsible for funding the clinical development of PTX-9908 in China. Pertinax will receive a royalty in connection with the sales of the product in China, as well as any future assignment or transfer of the rights.

PTX-9908 is an analog of Stromal Derived Factor -1 (SDF-1), a major chemotactic factor that plays a significant role in mediating cell trafficking via selective binding to CXCR4. When PTX-9908 binds to CXCR4, it stops the cancer cells from spreading to other parts of the body, a process called metastasis.

PTX-9908 has been tested in healthy human volunteers and cancer patients in several Phase I/II clinical trials in North America. These studies showed PTX-9908 to be safe and well-tolerated in human and preliminary evidence of efficacy was observed. MicroConstants China will conduct clinical research in China to establish the efficacy, safety and tolerability of PTX-9908 in patients with unresectable hepatocellular carcinoma using PTX-9908 infused intravenously.

"Our collaboration with MicroConstants China will enable expedited development of PTX-9908 in China and give us the opportunity to provide a potentially life-saving treatment to a large number of liver cancer patients with limited treatment options," said Dr. Bev Incledon, president of Pertinax. "With MicroConstants China's expertise in global drug development and their GLP/GCP compliance record, I am confident that data generated in China will complement our global development of PTX-9908 for the treatment of other cancers."

"The execution of this licensing agreement with Pertinax verifies our business model and is an important milestone for us," said Dr. Q. David Yang, chief executive officer of MicroConstants China. "PTX-9908 is an excellent candidate for liver cancer and our partner Pertinax has extensive preclinical and clinical expertise to support further development of the compound in China."

About Pertinax Therapeutics Inc.
Pertinax Therapeutics is a specialty pharmaceutical company leveraging networks to acquire, enhance and partner undervalued human-experienced drug candidates. Its lead product, PTX-9908, and a portfolio of SDF-1 mimetics, have significant therapeutic potential in cancer and autoimmune disorders due to their extensive clinical experience and robust data packages.

Pertinax's affiliated company, Concept 2 Clinic Inc., is an executive R&D management company specialized in the pharmaceutical and biotechnology sectors. They provide R&D leadership and infrastructure to pharmaceutical sponsors requiring virtual drug development expertise. For more information, please visit http://www.concept2clinic.com.

About MicroConstants China Inc.
MicroConstants China is a Site Management Organization (SMO) and Contract Research Organization (CRO) located in Beijing, China. Established in 2007 by the president of MicroConstants, Inc. in San Diego, California, MicroConstants China is focused on providing clinical trial management services, regulated bioanalysis, pharmacokinetic studies and quality system consulting to pharmaceutical and biotech companies. They also implement ICH GCP quality systems and provide clinical site management services to clinical trial centers in China. For more information, please visit http://www.microconstants.com.cn.



'/>"/>
SOURCE MicroConstants China Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants China Signs Site Management Organization Agreement with the Clinical Research Center of No. 307 Hospital
2. MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research
3. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
4. CentraState and Freehold Radiology Group train physicians from China
5. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
6. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
7. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
8. China Biologic Products Reports Higher Results for the First Quarter 2012
9. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
10. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
11. China Botanic Attends 67th PHARMCHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
Breaking Medicine Technology:
(Date:3/24/2017)... FL (PRWEB) , ... March 24, 2017 , ... ... Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, ... Master in Frederick, MD. Judy says, “I am passionate about sharing Reiki as ... a very difficult and challenging time.” , A Certified Medical Reiki™ Master trained ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and enlightened ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World War ... munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization declared ... be four million Zika-related cases in the Americas within the next year. Lyme disease ... reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect ...
Breaking Medicine News(10 mins):